Creative Biolabs possesses unchallenged experience in antibody engineering and recombinant protein generation. Multiple platforms of Creative Biolabs are elaborately integrated for providing customers one-stop services for bispecific antibody (BsAb) fragments development. Our cutting-edge techniques promise our BsAb products with not only high affinity and multiple valences to different targets, but also reliable safety for both academic and preclinical applications.
BsAb fragments lack some or all of the antibody constant domains. They are combination of antigen-binding units, such as Fv, scFv (single chain Fv), sdAbs (single domain antibody, such as VHH) and Fab, with or without some constant domains. Among BsAb fragments, tandem scFv, Diabody, nanobody-based antibody and their derivatives are the signature ones. The bispecific T cell engager (BiTE) is a type of tandem scFv and the first FDA-approved BsAb is just this format. Similarly, Diabody is generated by co-expressing of two scFv fragments with short linkers (1-10 amino acids). Besides the genetic engineering BsAb fragments, there are also Fab-based fragments developed by chemical-conjugation, such as F(ab’)2.
As a leading supplier, Creative Biolabs is committed to providing customers the most comprehensive list of BsAb products in the market. Highlighted by the recombinant antibody synthesis platform, multiple bio-engineering platforms in Creative Biolabs are integrated as a budget and time-saving working procedure. This platform is able to provide BsAb fragment products targeting any pair of antigens of interest. Classified by their size and backbone utilized, the customized BsAb fragment products include:
Figure 1. Alternative formats for BsAb fragments (Christoph Spiess et al. 2015)
As a global company, Creative Biolabs would like to share all its talented and well-trained scientists to support your drug development for the future.
Spiess, C.; et al. Alternative molecular formats and therapeutic applications for bispecific antibodies. Molecular immunology. 2015, 67(2): 95-106.